Black Diamond Therapeutics
Mario Corso has extensive experience in investor relations, currently serving as the Head of Investor Relations at Black Diamond Therapeutics, Compass Therapeutics Inc., and FORMA Therapeutics, Inc. Previously, Mario held the position of Senior Director of Investor Relations at ObsEva SA and was the Managing Partner at Access Capital Advisors. Mario Corso earned a Bachelor’s Degree in Economics from the University of Connecticut, attending from 1987 to 1991, and later continued education at Northeastern University from 1994 to 1996.
This person is not in any teams
Black Diamond Therapeutics
3 followers
Black Diamond Therapeutics is a leading venture-backed biotechnology company focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.